501 related articles for article (PubMed ID: 34104901)
1. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study.
Krutikov M; Palmer T; Tut G; Fuller C; Shrotri M; Williams H; Davies D; Irwin-Singer A; Robson J; Hayward A; Moss P; Copas A; Shallcross L
Lancet Healthy Longev; 2021 Jun; 2(6):e362-e370. PubMed ID: 34104901
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.
Krutikov M; Palmer T; Tut G; Fuller C; Azmi B; Giddings R; Shrotri M; Kaur N; Sylla P; Lancaster T; Irwin-Singer A; Hayward A; Moss P; Copas A; Shallcross L
Lancet Healthy Longev; 2022 Jan; 3(1):e13-e21. PubMed ID: 34935001
[TBL] [Abstract][Full Text] [Related]
3. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
[TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN).
Hall VJ; Foulkes S; Charlett A; Atti A; Monk EJM; Simmons R; Wellington E; Cole MJ; Saei A; Oguti B; Munro K; Wallace S; Kirwan PD; Shrotri M; Vusirikala A; Rokadiya S; Kall M; Zambon M; Ramsay M; Brooks T; Brown CS; Chand MA; Hopkins S;
Lancet; 2021 Apr; 397(10283):1459-1469. PubMed ID: 33844963
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with SARS-CoV-2 infection and outbreaks in long-term care facilities in England: a national cross-sectional survey.
Shallcross L; Burke D; Abbott O; Donaldson A; Hallatt G; Hayward A; Hopkins S; Krutikov M; Sharp K; Wardman L; Thorne S
Lancet Healthy Longev; 2021 Mar; 2(3):e129-e142. PubMed ID: 33655236
[TBL] [Abstract][Full Text] [Related]
7. Anti-nucleocapsid antibody levels following initial and repeat SARS-CoV-2 infections in a cohort of long-term care facility residents in England (VIVALDI).
Stirrup O; Tut G; Krutikov M; Bone D; Lancaster T; Azmi B; Monakhov I; Moss P; Hayward A; Copas A; Shallcross L
Wellcome Open Res; 2024; 9():45. PubMed ID: 38818129
[TBL] [Abstract][Full Text] [Related]
8. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
[TBL] [Abstract][Full Text] [Related]
9. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
Lumley SF; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Jeffery K; Eyre DW;
N Engl J Med; 2021 Feb; 384(6):533-540. PubMed ID: 33369366
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study.
Krutikov M; Stirrup O; Nacer-Laidi H; Azmi B; Fuller C; Tut G; Palmer T; Shrotri M; Irwin-Singer A; Baynton V; Hayward A; Moss P; Copas A; Shallcross L;
Lancet Healthy Longev; 2022 May; 3(5):e347-e355. PubMed ID: 35531432
[TBL] [Abstract][Full Text] [Related]
11. Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study.
Tut G; Lancaster T; Sylla P; Butler MS; Kaur N; Spalkova E; Bentley C; Amin U; Jadir A; Hulme S; Ayodele M; Bone D; Tut E; Bruton R; Krutikov M; Giddings R; Shrotri M; Azmi B; Fuller C; Baynton V; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2022 Jul; 3(7):e461-e469. PubMed ID: 35813280
[TBL] [Abstract][Full Text] [Related]
12. Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks.
Gallichotte EN; Nehring M; Young MC; Pugh S; Sexton NR; Fitzmeyer E; Quicke KM; Richardson M; Pabilonia KL; Ehrhart N; Fosdick BK; VandeWoude S; Ebel GD
Microbiol Spectr; 2021 Sep; 9(1):e0022421. PubMed ID: 34287058
[TBL] [Abstract][Full Text] [Related]
13. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.
Jeffery-Smith A; Rowland TAJ; Patel M; Whitaker H; Iyanger N; Williams SV; Giddings R; Thompson L; Zavala M; Aiano F; Ellis J; Lackenby A; Höschler K; Brown K; Ramsay ME; Gopal R; Chow JY; Ladhani SN; Zambon M
Lancet Healthy Longev; 2021 Dec; 2(12):e811-e819. PubMed ID: 34873592
[TBL] [Abstract][Full Text] [Related]
14. Antibody Seroprevalence, Infection and Surveillance for SARS-CoV-2 in Residents and Staff of New Jersey Long-Term Care Facilities.
Friedman SM; Davidow AL; Gurumurthy M; Peymani R; Webb J; Desai K; Siderits R; Nepomich A; Lifshitz E; Thomas PA
J Community Health; 2022 Oct; 47(5):774-782. PubMed ID: 35704225
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
Letizia AG; Ge Y; Vangeti S; Goforth C; Weir DL; Kuzmina NA; Balinsky CA; Chen HW; Ewing D; Soares-Schanoski A; George MC; Graham WD; Jones F; Bharaj P; Lizewski RA; Lizewski SE; Marayag J; Marjanovic N; Miller CM; Mofsowitz S; Nair VD; Nunez E; Parent DM; Porter CK; Santa Ana E; Schilling M; Stadlbauer D; Sugiharto VA; Termini M; Sun P; Tracy RP; Krammer F; Bukreyev A; Ramos I; Sealfon SC
Lancet Respir Med; 2021 Jul; 9(7):712-720. PubMed ID: 33865504
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
17. Antibody tests for identification of current and past infection with SARS-CoV-2.
Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
[TBL] [Abstract][Full Text] [Related]
18. Early Adoption of Longitudinal Surveillance for SARS-CoV-2 among Staff in Long-Term Care Facilities: Prevalence, Virologic and Sequence Analysis.
Gallichotte EN; Quicke KM; Sexton NR; Fitzmeyer E; Young MC; Janich AJ; Dobos K; Pabilonia KL; Gahm G; Carlton EJ; Ebel GD; Ehrhart N
Microbiol Spectr; 2021 Dec; 9(3):e0100321. PubMed ID: 34756092
[TBL] [Abstract][Full Text] [Related]
19. Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI).
Stirrup O; Shrotri M; Adams NL; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
Open Forum Infect Dis; 2023 Jan; 10(1):ofac694. PubMed ID: 36713473
[TBL] [Abstract][Full Text] [Related]
20. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
